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A B S T R A C T
Background
Intercostal catheters are commonly used for the drainage of intrathoracic collections in newborn infants, including pneumothorax and
pleural effusions. Placement of an intercostal drain is a potential risk factor for nosocomial infection due to breach of the cutaneous
barrier. Therefore, neonates who require intercostal drainage, especially those in high risk groups for nosocomial infection, may benefit
from antibiotic prophylaxis. However, injudicious antibiotic use carries the risk of promoting the emergence of resistant strains of
micro-organisms or of altering the pattern of pathogens causing infection.
Objectives
To determine the effect of prophylactic antibiotics compared to selective use of antibiotics on mortality and morbidity (especially
septicaemia) in neonates undergoing placement of an intercostal catheter.
Search methods
The standard search strategy of the Cochrane Neonatal Review Group was used to search the Cochrane Central Register of Controlled
Trials (CENTRAL) (The Cochrane Library 2011, Issue 5), MEDLINE (1948 to June 2011) and CINAHL (1982 to June 2011).
Selection criteria
Randomised controlled trials or some types of non-randomised (that is, quasi-randomised) controlled trials of adequate quality in
which either individual newborn infants or clusters of infants were randomised to receive prophylactic antibiotics versus placebo or no
treatment.
Data collection and analysis
We used the standard methods of the Cochrane Neonatal Review Group.
Main results
We did not find any randomised controlled trials that met the eligibility criteria.
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Authors’ conclusions
There are no data from randomised trials to either support or refute the use of antibiotic prophylaxis for intercostal catheter insertion
in neonates. Any randomised controlled trials of antibiotic prophylaxis would need to account for the fact that neonates who require
insertion of an intercostal catheter may already be receiving antibiotics for other indications.
P L A I N L A N G U A G E S U M M A R Y
Prophylactic antibiotics to reduce morbidity and mortality in newborn infants with intercostal catheters
There is no evidence to support or refute the use of preventive antibiotics in newborn babies with drainage tubes placed in the chest.
Sick newborn babies occasionally need the insertion of a tube that is placed through the skin and into the lung space to drain air or
fluid from around their lungs. Because this process involves breaching the skin barrier, there is a potential risk of infection. The group
of babies most likely to need this procedure are also those that are most at risk of developing an infection during their stay in hospital.
Preventive antibiotics are commonly used when there is a risk of infection, but they may have unwanted effects. The review authors
found no evidence to support or refute the use of routine preventive antibiotics when intercostal catheters are inserted in newborn
babies.
B A C K G R O U N D
Description of the condition
Intercostal catheters are commonly used for the drainage of in-
trathoracic collections in newborn infants, including pneumoth-
orax and pleural effusions. Placement of intercostal catheters is
common in critically ill neonates, especially in infants with birth-
weight less than 1500 g (very low birth weight infants, VLBW).
The Vermont Oxford Network Database reported an incidence
of pneumothorax in VLBW infants ranging from 5.1% to 8.6%
(1991 to 1996) (Horbar 2002).
As with any procedure involving breach of the cutaneous barrier,
intercostal drainage is a potential risk factor for nosocomial infec-
tion. Additionally, by virtue of their underlying illness, patients re-
quiring intercostal catheters may have impaired local and systemic
defence mechanisms. Premature and low birth weight infants are
particularly at risk. Retrospective data from the National Institute
of Child Health and Development (NICHD) Neonatal Research
Network,USA, demonstrated an incidence of pneumothorax from
1990 to 2002 of 13% in infants weighing 501 to 750 g and 6%
in infants weighing 751 to 1000 g (Fanaroff 2007). In these same
populations, the incidence of late-onset septicaemia was 44% and
30% respectively. Hence, the group of premature neonates most
likely to require an intercostal catheter are also those most at risk
of morbidity and mortality as a result of nosocomial infection.
Infection secondary to the use of intercostal catheters may cause
significant morbidity and mortality. Morbidity may include pro-
longed duration and increased severity of respiratory illness (in-
cluding chronic lung disease and the need for respiratory sup-
port) (Greenough 2005), increased length of hospital stay (Mireya
2007) and impaired neurodevelopmental outcomes (Stoll 2004).
Documented complications of intercostal catheters in both pae-
diatric and adult populations include localised cellulitis (Margau
2006) and empyema (Bailey 2000). The incidence of empyema
following intercostal drainage has been reported at about 2%
(Millikan 1980; Chan 1997; Bailey 2000). Potential factors to be
implicated in infection of the drain site and pleural space include
failure of the aseptic technique, advancement of a pre-existing
drain into the pleural space and duration of intercostal drainage
(Tang 2002). Factors that might affect the risk of infection, in-
cluding geographic location of insertion (operating theatre, inten-
sive care unit, retrieval site), patient acuity at the time of catheter
placement, and the skill level of the operator, have been incom-
pletely studied (Baumann 2003).
There are currently no published recommendations on the use of
prophylactic antibiotics for intercostal catheters for non-traumatic
indications. In adult chest trauma patients requiring intercostal
drainage, several studies have found evidence of benefit from sin-
gle-dose antimicrobial prophylaxis (Grover 1977; LeBlanc 1985;
Demetriades 1991) and published evidence-based guidelines for
chest trauma make a level III recommendation (based on class I
and II data) for up to 24 hours of cover with a first generation
cephalosporin (Luchette 2000). However, for non-traumatic indi-
cations across all age groups there remains variability in practice,
including the timing, target population and choice of antibiotics.
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Description of the intervention
Antibiotic prophylaxis is the administration of antibiotics with the
goal of reducing the risk of bacterial infection (Antibiotic Expert
Group 2006). In practice, antibiotic prophylaxis is used where
there is an increased risk of infection or where the consequence of
infection would be significant. The specific choice of antibiotic is
determined by the known or likely target organisms.
How the intervention might work
With any invasive procedure, including insertion of an intercostal
catheter, there is a risk of the introduction of colonising bacteria
into the systemic circulation (Dear 2005). The use of antibiotic
prophylaxis against known or likely target organisms would po-
tentially reduce pathogen load and, therefore, minimise local and
systemic infection related to intercostal catheter use.
Why it is important to do this review
There are significant public health implications for failure of ju-
dicious antibiotic use (CDC 2004). Antimicrobial prophylaxis,
while potentially preventing intercostal catheter-related soft tis-
sue and bloodstream infection, may have the undesirable effect
of promoting the emergence of resistant strains of micro-organ-
isms (Freij 1999) or of altering the pattern of pathogens causing
infection (Viudes 2002). At the individual level, there is a risk of
adverse effects associated with antibiotic use including ototoxicity
and nephrotoxicity (Fanos 1999; Contopoulos-Ioannidis 2004).
Any policy of antimicrobial prophylaxis must take these potential
risks into account.
Recent Cochrane systematic reviews on the use of prophylactic
antibiotics for neonates with umbilical artery catheters (Inglis
2007), umbilical venous catheters (Inglis 2005) and central venous
catheters (Jardine 2008) demonstrated that there was no evidence
to either support or refute the use of antimicrobial prophylaxis
during the use of such catheters in newborn infants. The following
systematic review evaluated the use of prophylactic antibiotics for
neonates with intercostal catheters.
O B J E C T I V E S
To determine the effects of prophylactic antibiotics compared to
selective use of antibiotics on mortality and morbidity (especially
septicaemia) in neonates undergoing placement of an intercostal
catheter.
Pre-specified subgroup analyses:
1. term (≥ 37 weeks gestation) versus preterm (< 37 weeks
gestation);
2. type of antibiotic (e.g., penicillins, macrolides,
aminoglycosides, cephalosporins, or combinations);
3. indication for catheter (e.g., pneumothorax (not post-
operative), pleural effusion, post-operative indications);
4. type of prophylaxis (e.g., single dose(s) with insertion,
ongoing prophylaxis for the life of the catheter);
5. whether infant was on antibiotics at the time of study entry.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs) or some types of non-ran-
domised (that is, quasi-randomised) controlled trials of adequate
quality in which either individual newborn infants or clusters of
infants (such as separate neonatal units) were randomised to re-
ceive prophylactic antibiotics versus placebo or no treatment.
Types of participants
Neonates with intercostal catheters: full term infants less than 28
days old; preterm infants up to 44 weeks post-menstrual age.
Types of interventions
Any systemic antibiotic (not including antifungals) or combina-
tion of antibiotics, either as a single dose or ongoing prophylaxis,
versus placebo or no treatment given at the time of catheter in-
sertion. We did not specifically exclude any study that enrolled
babies who were or were not receiving a treatment course (or dose
or doses) of antibacterial antibiotics.
Types of outcome measures
Primary outcomes
• Mortality (neonatal mortality, mortality prior to discharge,
or however defined in individual studies)
• Proven bacterial septicaemia (blood culture positive),
suspected septicaemia, or clinical septicaemia
3Prophylactic antibiotics to reduce morbidity and mortality in newborn infants with intercostal catheters (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Secondary outcomes
• Incidence of cellulitis (local soft tissue infection causing
inflammation)
• Incidence of empyema (a collection of pus in the pleural
space)
• Chronic lung disease (oxygen requirement at 36 weeks
post-menstrual age)
• Duration of ventilation (hours or days)
• Duration of respiratory support (hours or days)
• Duration of oxygen therapy (hours or days)
• Duration of hospital stay (days)
• Number of resistant organisms (i.e., species) causing
infection, identified per time period per infant or per cluster unit
(resistance however defined in individual studies)
• Number of resistant organisms (i.e., species) colonising
infants in the study, identified per time period per infant
(resistance however defined in individual studies)
• Number of resistant organisms (i.e., species) colonising all
infants identified per time period per cluster unit (resistance
however defined in individual studies)
• Neurodevelopmental outcome (cerebral palsy, sensorineural
hearing loss, visual impairment or developmental delay) at one
year, 18 months, two years, or five years
Search methods for identification of studies
We used the standard methods of the Cochrane Neonatal Review
Group.
Electronic searches
We searched the Cochrane Central Register of Controlled Trials
(CENTRAL) (The Cochrane Library, Issue 5, 2011), MEDLINE
(1948 to June 2011) and CINAHL (1982 to June 2011) using the
following strategy.
MeSH search terms “Thoracostomy” OR “Chest Tubes” OR the
textwords ((“intercostal” OR “inter-costal”) AND “cathet$”) OR
“ICC” OR “ICTD” OR “chest drain” OR “chest tube” OR “tube
thoracostomy” OR “tube thoracotomy”
AND
MeSHsearch term“Infant, newborn”OR the textwords “neonat$”
OR “infant”
AND
MeSH search term “Anti-Bacterial Agents” OR the textword “an-
tibiotic”
AND
MeSH search terms “Chemoprevention” OR “Antibiotic Prophy-
laxis” OR the textword “prophyl$”.
Searching other resources
We also searched previous reviews (including cross references).We
did not restrict the searches to publications in the English language
or published data. We planned to contact authors for additional
or missing information.
Data collection and analysis
The review authors planned to separately extract, assess and code
all data for each study using a form that was designed specifically
for this review. It was planned to replace any standard error of
the mean with the corresponding standard deviation (SD = se X
sq root N). Any disagreement was to be resolved by discussion.
For each study, final data would be entered into RevMan by one
review author and then checked by a second review author. Any
disagreements would be addressed by a third review author.
Selection of studies
We planned to include all randomised, quasi-randomised con-
trolled trials or cluster trials fulfilling the selection criteria de-
scribed in the previous section. Two of the review authors (AS and
PK) independently searched for and assessed trials for inclusion
and methodological quality. We planned to resolve any disagree-
ment by discussion.
Data extraction and management
We planned to employ the standard methods of the Cochrane
Neonatal Review Group. Data for any included studies were to
be extracted independently by at least two of the review authors
for each of the available outcomes, as listed above, and the data
entered into Revman 5.
Assessment of risk of bias in included studies
It was intended that two of the review authors would indepen-
dently assess risk of bias for each study using the criteria outlined
in the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2008). Any disagreement was to be resolved by discus-
sion with or by involving a third review author.
The methodological quality of the studies was to be assessed using
the following criteria.
1) Sequence generation (evaluating possible selection bias). For
each included study, description of the method used to generate
the allocation sequence as: low risk (any truly random process
e.g., random number table, computer random number generator);
high risk (any non-random process e.g., odd or even date of birth,
hospital or clinic record number); or unclear risk.
2) Allocation concealment (evaluating possible selection bias). For
each included study, description of the method used to conceal
the allocation sequence as: low risk (e.g., telephone or central ran-
domisation, consecutively numbered sealed opaque envelopes);
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high risk (open random allocation, unsealed or non-opaque en-
velopes, alternation, date of birth); or unclear risk.
3) Blinding (evaluating possible performance bias). For each in-
cluded study, we planned to provide a description of the methods
used to blind study participants and personnel from knowledge
of which intervention a participant received. Blinding was to be
assessed separately for different outcomes or classes of outcomes.
We planned to assess the methods as: low risk, high risk or unclear
risk for participants; low risk, high risk or unclear risk for person-
nel; and low risk, high risk or unclear risk for outcome assessors.
4) Incomplete outcome data (evaluating possible attrition bias
through withdrawals, dropouts, protocol deviations). For each in-
cluded study, and for each outcome, we planned to describe the
completeness of data including attrition and exclusions from the
analysis.We planned to state whether attrition and exclusions were
reported, the numbers included in the analysis at each stage (com-
pared with the total number of randomised participants), reasons
for attrition or exclusionwhere reported, andwhethermissing data
were balanced across groups or were related to outcomes. Where
sufficient information was reported or could be supplied by the
trial authors, we intended to re-include missing data in the analy-
ses that we undertook. We planned to assess methods as: low risk
(< 20% missing data); high risk (≥ 20% missing data); or unclear
risk.
5) Selective reporting bias. For each included study, we planned to
describe how we investigated the possibility of selective outcome
reporting bias and what we found. Methods would be assessed
as: low risk (where it was clear that all of the study’s pre-specified
outcomes and all expected outcomes of interest to the review had
been reported); high risk (where not all the study’s pre-specified
outcomes had been reported, one or more of the reported pri-
mary outcomes were not pre-specified, outcomes of interest were
reported incompletely and so could not be used, study failed to
include results of a key outcome that would have been expected
to have been reported); or unclear risk.
6) Other sources of bias. For each included study, we planned
to describe any important concerns we had about other possible
sources of bias (e.g., whether there was a potential source of bias
related to the specific study design or whether the trial was stopped
early due to some data-dependent process). It was planned to assess
each study as to whether it was free of other problems that could
put it at risk of bias as: yes; no; or unclear.
Measures of treatment effect
For individual study results, for continuous variables themean dif-
ferences (MD) and 95% confidence intervals were to be reported.
For categorical outcomes we planned to report the relative risks
(RR) and 95% confidence intervals. For significant findings, we
intended to calculate the risk difference (RD) and number needed
to treat (NNT). For measures of counts and rates, we planned to
calculate rate ratios.
Assessment of heterogeneity
We planned to assess heterogeneity using the I2 statistic test of
heterogeneity where sufficient included studies were available.
Data synthesis
We planned to perform the analysis using Review Manager soft-
ware (RevMan 5) supplied by The Cochrane Collaboration, if
meta-analysis was judged to be appropriate. We planned to report
weighted mean differences (WMD) for pooled results of contin-
uous variables, and 95% confidence intervals. We planned to use
theMantel-Haenszel method for estimates of a typical relative risk
and risk difference.We planned to use the inverse variance method
for measured quantities. All meta-analyses were to be done using
the fixed-effect model.
Subgroup analysis and investigation of heterogeneity
Data permitting, subgroup analysis was to be done in order to
determine whether results differed by:
1. term (≥ 37 weeks gestation) versus preterm (< 37 weeks
gestation);
2. type of antibiotic (e.g., penicillins, macrolides,
aminoglycosides, cephalosporins, or combinations);
3. indication for catheter (e.g., pneumothorax (not post-
operative), pleural effusion, post-operative indications);
4. type of prophylaxis (e.g., single dose(s) with insertion,
ongoing prophylaxis for the life of the catheter);
5. whether infant was on antibiotics at the time of study entry.
Sensitivity analysis
Given availability of sufficient data, a sensitivity analysis was
planned to see if results differed by the quality of the included stud-
ies (for example, adequacy of randomisation, quasi-randomised
versus randomised).
R E S U L T S
Description of studies
See: Characteristics of excluded studies.
Results of the search
One study was retrieved using the above search strategy, but was
not eligible for inclusion in this review.
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Included studies
No studies met the criteria for inclusion in this review.
Excluded studies
See: Characteristics of excluded studies
Patel 2009 was a retrospective observational study of antibiotic
use in neonatal intensive care units. It was a non-randomised con-
trolled trial which did not meet our inclusion criteria for study
design.
Risk of bias in included studies
No studies met the criteria for inclusion in this review.
Effects of interventions
No studies met the criteria for inclusion in this review.
D I S C U S S I O N
We did not find any randomised controlled trials that assessed
the effects of antibiotic prophylaxis on mortality and morbidity in
neonates with intercostal catheters. Although it is plausible that
premature neonateswho require insertion of an intercostal catheter
are likely to be at high risk of nosocomial infection and might
therefore benefit from antibiotic prophylaxis, there are no data
available to indicate whether antibiotic prophylaxis in this patient
group reduces mortality and morbidity.
The only published randomised prospective trials of antibiotic
prophylaxis for intercostal catheter insertion have been performed
in adult chest trauma populations. Grover 1977 and LeBlanc 1985
found evidence of benefit from prophylaxis, and Demetriades
1991 found single-dose prophylaxis to be as effective as prolonged
prophylaxis. There are no published studies addressing the use of
antibiotic prophylaxis for intercostal catheters for non-traumatic
indications in any age group. Nonetheless, the use of antibiotic
prophylaxis for intercostal catheter insertion in the neonatal pop-
ulation has been reported (Patel 2009) and, in the absence of any
evidence of benefit, concerns remain regarding the role of this prac-
tice in the development of antimicrobial resistance (CDC 2004;
Patel 2009).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
There are nodata from randomised trials to either support or refute
the use of antibiotic prophylaxis for intercostal catheter insertion
in neonates.
Implications for research
A large randomised controlled trial would be needed for an unbi-
ased assessment of the effect of antibiotic prophylaxis in neonates
with intercostal catheters and would need to account for the fact
that neonates who require insertion of an intercostal catheter may
already be receiving antibiotics for other indications. For this rea-
son it is unlikely such a trial would be practical. In addition, clini-
cians do not commonly attribute nosocomial infection to the pres-
ence of an intercostal catheter and there may be little enthusiasm
for such a trial.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Patel 2009 Multicentre retrospective observational study of antibiotic use in neonatal intensive care units. Not a RCT, did not meet
inclusion criteria
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